

RENEO PHARMACEUTICALS, INC.
18575 Jamboree Road, Suite 275-S
Irvine, CA 92612

August 23, 2024

VIA EDGAR

United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Gary Newberry
Lynn Dicker
Tyler Howes
Tim Buchmiller

Re: Reneo Pharmaceuticals, Inc.
Registration Statement on Form S-4 (File No. 333-280369)
Request for Acceleration of Effective Date

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Reneo Pharmaceuticals, Inc. (the “**Company**”) hereby respectfully requests that the U.S. Securities and Exchange Commission accelerate the effective date and time of the above referenced Registration Statement on Form S-4 (the “**Registration Statement**”) and declare the Registration Statement effective as of 4:30 p.m. Eastern Time on August 26, 2024, or as soon thereafter as practicable.

The Company requests that it be notified of such effectiveness by a telephone call to either Bradley C. Brassler of Jones Day at (612) 217-8886 or Jonn R. Beeson of Jones Day at (949) 553-7528. Thank you for your attention to this matter.

cc: Bradley C. Brassler, Jones Day
Jonn R. Beeson, Jones Day

Sincerely,

Reneo Pharmaceuticals, Inc.

/s/ Gregory J. Flesher

Gregory J. Flesher

President and Chief Executive Officer